MLYS (Mineralys Therapeutics) Ending Cash Position: $112.78 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLYS Mineralys Therapeutics Inc MLYS
37 GF Score
Price $26.74
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Ending Cash Position?

Mineralys Therapeutics MLYS -1.09% 37 Ending Cash Position is $112.78 Mil as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Mineralys Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $112.78 Mil.

Mineralys Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($217.60 Mil) to Dec. 2025 ($172.92 Mil) and declined from Dec. 2025 ($172.92 Mil) to Mar. 2026 ($112.78 Mil).

Mineralys Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($49.30 Mil) to Dec. 2024 ($114.09 Mil) and increased from Dec. 2024 ($114.09 Mil) to Dec. 2025 ($172.92 Mil).

Mineralys Therapeutics Ending Cash Position Related Terms

Mineralys Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Ending Cash Position Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 10.66 87.70 49.30 114.09 172.92

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.01 101.79 217.60 172.92 112.78
MLYS
37GF Score
Mineralys Therapeutics Inc MLYS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Mineralys Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=114.091+58.83
=172.92

Mineralys Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=172.921+-60.142
=112.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $112.78 Mil mean?
Mineralys Therapeutics (MLYS) has a Ending Cash Position of $112.78 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Ending Cash Position too high?
Mineralys Therapeutics' current Ending Cash Position is $112.78 Mil. Overall, Mineralys Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Ending Cash Position compare to VCEL and NRIX?
Mineralys Therapeutics' Ending Cash Position of $112.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Ending Cash Position is $112.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Ending Cash Position of $112.78 Mil. The current Ending Cash Position is $112.78 Mil. Mineralys Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Ending Cash Position is $112.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
37GF Score

Get the complete analysis for MLYS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.74
Price